Is ABT a good stock to buy?
Abbott Laboratories · end-of-day data as of Nov 13, 2026
- PT$121.32 +11.8%
- ConsensusBuy · 28
- MAs4 of 4
- MA20×50Golden 7d ago
- Sector▲ +15.9%
- Earnings in76d
- P/E40.2x
- RSI54
- Support-1.6%
- Resistance+2.2%
- Off 52w high-17.8%
- Volume0.7x
- Bollingerupper half
- News1.00
- Trendsideways
- 52w range$82–$132
- ATR+2.7%
- Off ATH-23.9%
- P/E vs own+25.6%
- P/E vs sector+24.8%
- Insiders-$46.61M
- MACD-0.08
Updates with the 15-min delayed price. Not a forecast or investment advice.
Is Abbott a good stock to buy?
Abbott is strong on 1 of the 5 questions about the business; weak on advantage and execution. The price is high: 40.2 times its earnings, above its 3-year median of 31.0 (Nov 13, 2026). pretickt does not say whether to buy or sell.
- Demand steady
- Advantage easy to copy
- Economics profitable
- Execution misses
- Fragility sturdy
- Price expensive
ABT sales growth revenue growth
+1%a year, for the last 3 yearsAbbott's sales grew 1% a year for 3 years, to $44.33B in fiscal 2025.
ABT analysts' forecast revenue estimates
+13%the sales they expect next fiscal year, on the lastAnalysts expect Abbott's sales to grow 13% to $49.98B in fiscal 2026 (20 analysts).
ABT competitors
pretickt analysis+10%its sales in 12 months, on a year before
Abbott's sales grew 10% in the 12 months to Sep 30, 2026, faster than Boston Scientific (+9%) and Stryker (+8%), slower than Edwards Lifesciences (+13%).
ABT sales by business revenue by segment
48%of its sales from Medical DevicesMedical Devices brought Abbott 48% of its sales in fiscal 2025; Diagnostic Products 20%.
ABT return on capital ROIC
pretickt analysis9%earned before tax on the money invested in itAbbott earned 9% before tax on the capital invested in it in the 12 months to Sep 30, 2026; Edwards Lifesciences 16%, Stryker 16% and Boston Scientific 12%.
ABT margin on each sale gross margin
57%left after making the productAbbott kept 57% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 70%.
ABT margin after costs profit margin
15%of sales left after running the businessAbbott's operating margin was 15% in the 12 months to Sep 30, 2026, against 19% in fiscal 2022.
ABT earnings vs estimates
3 of 8quarters above the analysts' estimateAbbott beat the analysts' profit estimate in 3 of its last 8 quarters, the latest on Oct 21, 2026.
ABT insider selling
-$43.54Msold, net, by its executives in 12 monthsAbbott's executives and directors sold a net $43.54M of shares in the 12 months to Nov 13, 2026 ($47.94M sold, $4.4M bought).
ABT number of employees
+1%more people in a yearAbbott had 115,000 employees at the end of fiscal 2025, 1% more than a year before.
ABT CEO pay
$24.2Mfor fiscal 2025, 73% of it in stock and optionsAbbott paid its CEO $24.2M for fiscal 2025, 73% of it in stock and options.
ABT financial health Altman Z-score
3.4Altman Z-score, safe above 3Abbott's Altman Z-score is 3.4 (Nov 13, 2026), above 3, where the safe zone starts.
ABT in past recessions
pretickt analysis+4%its sales in the worst oneAbbott's sales grew through each of the last 2 US recessions (2008–09 and 2020).
ABT price vs profit P/E ratio
40.2×a year's earningsAbbott's P/E ratio is 40.2 (Nov 13, 2026), above its 3-year median of 31.0.
ABT price vs competitors
pretickt analysis40.2×a year's earnings, against its competitors
Investors pay 40.2 times Abbott's earnings (Nov 13, 2026), more than for Stryker (33.0) and Boston Scientific (18.8), less than for Edwards Lifesciences (60.5).
ABT analysts' target price target
+12%to their average targetAnalysts' average price target for Abbott is $121, 12% above the Nov 13, 2026 close of $108.52.
ABT analyst ratings, 90 days
pretickt analysisRothschild & Coupgrade Argus Researchdowngrade
In the 90 days to Nov 13, 2026, Rothschild & Co upgraded Abbott; Argus Research downgraded it.
What is Abbott's P/E ratio?
Abbott's P/E ratio is 40.2 (Nov 13, 2026), above its 3-year median of 31.0. Investors pay 40.2 times Abbott's earnings (Nov 13, 2026), more than for Stryker (33.0) and Boston Scientific (18.8), less than for Edwards Lifesciences (60.5).
Who are Abbott's biggest competitors?
pretickt compares Abbott with Medtronic, Stryker, Boston Scientific and Edwards Lifesciences. Abbott's sales grew 10% in the 12 months to Sep 30, 2026, faster than Boston Scientific (+9%) and Stryker (+8%), slower than Edwards Lifesciences (+13%).
Is Abbott profitable?
Abbott's operating margin was 15% in the 12 months to Sep 30, 2026, against 19% in fiscal 2022.
Are insiders selling Abbott stock?
Abbott's executives and directors sold a net $43.54M of shares in the 12 months to Nov 13, 2026 ($47.94M sold, $4.4M bought).
How does Abbott make money?
Medical Devices brought Abbott 48% of its sales in fiscal 2025; Diagnostic Products 20%.
Who owns Abbott stock?
3,076 institutions hold 82% of Abbott's shares (Jun 30, 2026); Vanguard, BlackRock and State Street added shares that quarter.
How many employees does Abbott have?
Abbott had 115,000 employees at the end of fiscal 2025, 1% more than a year before.
From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.